Recent population‐based studies have shown encouraging results, with a large cohort study demonstrating reduced risk of dementia in SGLT2 inhibitor users compared to DPP‐4 inhibitor users, particularly after 2 years of treatment (Shin et al. 2024). This evidence concerns the gene SLC5A2 and dementia.